Related Experiment Video
Updated: Aug 6, 2026

14:14
Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis
Published on: April 29, 2007
Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication
R J Lederman1, A N Tenaglia, R D Anderson
1Department of Internal Medicine, Division of Cardiology, University of Michigan Health System, Ann Arbor, Michigan, USA.
The American Journal of Cardiology
|July 13, 2001
Abstract:
The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) is a large, randomized, placebo-controlled, regimen-finding trial of intra-arterial recombinant fibroblast growth factor-2 in patients with intermittent claudication. This report describes the major design considerations and end points in TRAFFIC.

